Navigation Links
Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting
Date:11/17/2016

NORTHBROOK, Ill., Nov. 17, 2016 /PRNewswire/ -- Astellas today announced two gilteritinib abstracts, including an oral presentation in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML), that will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, Dec. 3-6 in San Diego.

The following abstract will be presented during an oral presentation session:

Continue Reading
Astellas is a pharmaceutical company dedicated to improving the health of people around the world.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world.

Title: Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). (Abstract 1069)

Presenter: Alexander E. Perl, M.D., University of Pennsylvania-Abramson Comprehensive Cancer Center, Philadelphia, Pa.

  • Session Date/Time: Monday, Dec. 5 at 4:30 p.m. PST
  • Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)

In addition to the oral presentation, Astellas will present the following abstract in a poster session:

Title: Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia (Yoko Ueno, PhD) (Abstract 2830)

  • Session Date/Time: Sunday, Dec. 4 from 6:00 p.m. to 8:00 p.m. PST
  • Location: Hall GH (San Diego Convention Center)

About Astellas

Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.

Logo - http://photos.prnewswire.com/prnh/20140416/84970

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astellas-oncology-announces-new-data-in-acute-myeloid-leukemia-to-be-presented-at-the-2016-ash-annual-meeting-300365503.html


'/>"/>
SOURCE Astellas
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen
2. Amgen And Astellas Announce Japan Alliance
3. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the FedEx St. Jude Classic
4. Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
5. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the AT&T National
6. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
7. Astellas Appoints New Senior Vice President of Global Oncology Development
8. Astellas Confirms Interim Analysis in PREVAIL Study of XTANDI will Occur within Calendar Year 2013
9. Astellas to Host Executive Womens Day at 2013 TOUR Championship by Coca-Cola
10. Astellas Employees to Change Tomorrow through Annual Day of Service
11. Astellas US Appoints Senior Vice President, Chief Communications Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2018)... ... October 12, 2018 , ... ... open, welcoming applications from healthcare providers, students, trainees, and researchers worldwide. Winning proposals ... as microbiome sequencing and bioinformatics services. , “uBiome is thrilled to further expand ...
(Date:10/13/2018)... Fla. (PRWEB) , ... October 13, 2018 , ... In ... period taking on one massive brand after another. 2018 has been a game-changing year ... categories have all played a large role in the growth. Ion Labs attributes its ...
(Date:10/11/2018)... ... 11, 2018 , ... In the last four months it has also obtained ... allowance of six more in USA, China and Japan from three other patent families ... and security products. , The patents assigned from QinetiQ include US 7113092, titled “Ferromagnetic ...
Breaking Medicine Technology:
(Date:10/16/2018)... ... October 15, 2018 , ... LGC Maine Standards ... Number 205bf, for easier linearity and calibration verification. , The kit, in ... verification and verification of the reportable range for Albumin (ALB), Amylase (AMY), Cholesterol ...
(Date:10/16/2018)... (PRWEB) , ... October 16, ... ... a Texas-based healthcare and clinical research networking-technology company founded by patient-survivors, and ... quality and compliance in the clinical trial execution process, today announced its ...
(Date:10/13/2018)... ... 2018 , ... Convoy of Hope’s Disaster Services Team is currently in Marianna, ... set up to serve hurricane survivors with water, food, baby products, hygiene kits, flood ... additional truckloads of supplies are in motion to Florida. , Convoy’s walk-up ...
(Date:10/11/2018)... CHURCH, Va. (PRWEB) , ... October 11, 2018 ... ... and services, today announced the acquisition of J.Lodge, an industry leader in contact ... story —a lifelong survivor of a debilitating medical condition—J. Lodge supports alternative work ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... and quite vulnerable to manipulation,” warns former U.S. Department of Homeland Security deputy ... We’re Vulnerable and How We Can Stop it. , Pointing to the ability ...
Breaking Medicine News(10 mins):